CClinicalTrials.gg
Not yet recruitingNCT07068243RESTUpdated Jun 17, 2026

REctus Sheath Trial

A Phase 2 interventional study of 1.0% lidocaine with epinephrine (1:100,000) in Acute Pain and Postoperative Pain, Acute, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Duke University · Phase 2, Interventional, and Other

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the abdominal wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. The rectus sheath block (RSB) is an established regional anesthesia technique used to provide somatic analgesia to the midline anterior abdominal wall by depositing local anesthetic in the posterior rectus sheath, thereby targeting the terminal anterior branches of the lower thoracic intercostal nerves. The conventional approach involves placing the ultrasound (US) probe transversely across the rectus abdominis muscle and advancing the needle in-plane either lateral-to-medial or medial-to-lateral. While this technique achieves spread within the sheath, the cephalocaudal distribution of local anesthetic may be suboptimal, potentially limiting the extent of dermatomal coverage. A longitudinal probe orientation, with needle insertion from cephalad to caudad, may theoretically facilitate a more extensive cranio-caudal spread by aligning the injection axis with the anatomical fascial plane of the posterior rectus sheath. However, the relative efficacy of these two approaches has not been investigated in a controlled, comparative setting. Thus, this randomized, single-blinded trial aims to evaluate the dermatomal sensory distribution and ultrasound-assessed local anesthetic spread achieved by the transverse versus longitudinal in-plane approaches to ultrasound-guided RSB in healthy adult volunteers. To compare the dermatomal sensory block distribution, investigators will use dermatomal mapping with pinprick, and cold.

Read the detailed description

A total of 14-18 adult volunteers will be included. Each participant will receive bilateral rectus sheath blocks at a standardized supraumbilical level. The side receiving the transverse approach (US probe perpendicular to muscle fibers; needle in-plane lateral-to-medial) and the side receiving the longitudinal approach (US probe parallel to muscle fibers; needle in-plane cephalad-to-caudad) will be randomized. The blocks will be performed with a standardized volume and concentration of local anesthetic, under real-time US guidance by the same experienced anesthesiologist. The research team member assessing the block will be blinded. Immediately after injection of each block, US imaging will be used to assess and measure the length and pattern of spread within the posterior rectus sheath. At baseline and at 60 minutes post-block, dermatomal sensory mapping will be performed using standardized cold and pinprick stimuli over the anterior abdominal wall.

02

Conditions studied

  • Acute Pain
  • Postoperative Pain, Acute

Keywords

  • Rectus Sheath Block
  • Abdominal Block
  • Fascial Plane Block
  • RSB
03

In context

Acute Pain

876 studies on the registry are indexed under Acute Pain; 154 are open to participants now.

This study's planned enrollment of 25 is below the median of 90 across 732 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Ability to provide written informed consent
  2. Ability and willingness to comply with the study procedures and duration requirements
  3. ASA physical status 1 or 2
  4. Age ≥ 18 years
  5. Weight > 60kg

Exclusion criteria

Exclusion criteria:

  1. BMI > 40kg.m-2
  2. Use of analgesics within 24 hours before the procedure
  3. History of abdominal trauma or surgery
  4. Abdominal deformities or abnormalities that may prevent proper block performance
  5. Abdominal tattoos in the supraumbilical area
  6. Systemic neuromuscular disease
  7. Contraindications to regional anesthesia (e.g., infection, allergy)
  8. Structures are unable to be visualized by ultrasound
  9. Pregnancy
  10. Other known health conditions that would affect the participant's ability to successfully complete the study
05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Transverse Approach to the Rectus Sheath Block

    In the transverse approach, the US probe will be positioned perpendicular to the he rectus abdominis muscle's fibers, and the needle will be inserted in-plane from lateral to medial.

    Drug: 1.0% lidocaine with epinephrine (1:100,000)

  • Experimental
    Longitudinal Approach to the Rectus Sheath Block

    In contrast, the longitudinal approach will involve aligning the probe parallel to the rectus muscle fibers, with the needle advanced in-plane from cephalad to caudad.

    Drug: 1.0% lidocaine with epinephrine (1:100,000)

Interventions

  • Drug1.0% lidocaine with epinephrine (1:100,000)

    The block will be performed by advancing the needle into the posterior rectus sheath compartment, with the local anesthetic deposited posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath. Drug: 20 mL injection of 1.0% lidocaine with epinephrine (1:100,000) on each side (40mL total/subject)

06

What researchers measure

Primary outcomes

  1. Temperature discrimination

    Skin temperature assessment using gloved ice on the chest wall, to discriminate blocked vs unblock areas.

    Time frame: 60 to 90 minutes post-block

  2. Mechanical discrimination

    Mechanical assessment using a neuropin (pinprick) on the chest wall, to discriminate blocked vs unblock areas.

    Time frame: 60 to 90 minutes post-block

  3. Cutaneous distribution mapping

    Mapping the blocked area (using the previous temperature and mechanical assessments, demarcating lines on the skin) to provide a visual map and, to calculate the area blocked.

    Time frame: 60 to 90 minutes post-block

Secondary outcomes

  1. Direct visualization of the local anesthetic spread

    Direct visualization of the local anesthetic spread cephalad and caudad, marking the highest and lowest dermatomes where local anesthetic was still seen on the US, with the US oriented longitudinally.

    Time frame: Immediately post-block

  2. Measurement of the local anesthetic spread in each dermatome with the US

    Measurement of the local anesthetic spread in each dermatome with the US oriented transversely, by measuring hypoecoic area produced by the presence of local anesthetic.

    Time frame: Immediately post-block

Other outcomes

  1. Adverse Events

    Any adverse events block-related will be recorded

    Time frame: End of study (2 days post blocks).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068243
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Sep 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

David MacLeod, MBBS
Contact
david.macleod@duke.edu
9198123201
Sara Amaral, MD
Contact
sara.amaral@duke.edu
7373479570

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion